WALTHAM, Mass. , Oct. 18, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO), reported that DPNCheck ® , its rapid, point-of-care test for diabetic peripheral neuropathy (DPN), will be featured in several scientific sessions at the 33 rd Japan Society of Diabetic Complications Meeting in
WALTHAM, Mass. , Oct. 31, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix , Inc. (Nasdaq:NURO) announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. 10,112,040 titled “Transcutaneous electrical nerve stimulation using novel unbalanced biphasic waveform and novel electrode
WALTHAM, Mass. , Nov. 15, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO), announced today that it had executed a distribution agreement with Fukuda Denshi Co. Ltd. for DPNCheck ® , the Company’s rapid, point-of-care test for diabetic peripheral neuropathy (DPN).
WALTHAM, Mass. , Nov. 20, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix , Inc. (Nasdaq:NURO) announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. 10,130,810 titled “Transcutaneous electrical nerve stimulation with user gesture detector and electrode-skin contact detector,
WALTHAM, Mass. , Nov. 28, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix , Inc. (NASDAQ:NURO) today announced that Shai N. Gozani M.D., Ph.D., President and CEO of NeuroMetrix, is scheduled to speak at the upcoming LD Micro Annual Main Event at the Luxe Sunset Bel Air Hotel in Los Angeles, CA. Dr.
WALTHAM, Mass. , Dec. 11, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix , Inc. (Nasdaq: NURO) today reported momentum in its strategic collaboration with GSK Consumer Healthcare . Under terms of the collaboration entered into in the first quarter of 2018, the parties committed to co-fund future development
WALTHAM, Mass. , Dec. 19, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix , Inc. (Nasdaq:NURO) announced today that Shai N. Gozani M.D., Ph.D., President and Chief Executive Officer, will be presenting at the Biotech Showcase 2019 Conference at the Hilton San Francisco Union Square on Monday, January 7 ,
WALTHAM, Mass. , Dec. 27, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix , Inc. (Nasdaq:NURO) announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. 10,159,835 titled “Detecting cutaneous electrode peeling using electrode-skin impedance.” The patent covers novel methods of
The smart wearable harnessing the power of neurostimulation and AI to attack the chronic pain crisis LAS VEGAS, Jan. 07, 2019 (GLOBE NEWSWIRE) -- NeuroMetrix Inc. (Nasdaq: NURO) today unveiled its smartest, smallest and most powerful wearable therapeutic to date.
WALTHAM, Mass. , Jan. 08, 2019 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced that it has been named a CES ® 2019 Innovation Awards Honoree for Quell ® 2.0 Wearable Pain Relief Technology™ in the Fitness, Sports and Biotech product category.
